BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Accenture
QuintilesIMS
Cantor Fitzgerald
Farmers Insurance
Merck
Mallinckrodt
Argus Health
McKesson

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,838,464

« Back to Dashboard

Summary for Patent: 6,838,464
Title: 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents
Abstract:Pyrimidine derivatives of formula (I) wherein Q.sub.1, Q.sub.2, G and R.sup.1 are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described. ##STR1##
Inventor(s): Pease; Elizabeth Janet (Macclesfied, GB), Williams; Emma Jane (Macclesfield, GB), Bradbury; Robert Hugh (Macclesfield, GB), Pearson; Stuart Eric (Macclesfied, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:10/203,025
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 6,838,464

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gilead Sciences Inc COMPLERA emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate TABLET;ORAL 202123-001 Aug 10, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Janssen Prods EDURANT rilpivirine hydrochloride TABLET;ORAL 202022-001 May 20, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Gilead Sciences Inc ODEFSEY emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate TABLET;ORAL 208351-001 Mar 1, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,838,464

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0004887Mar 01, 2000
PCT Information
PCT FiledFebruary 26, 2001PCT Application Number:PCT/GB01/00829
PCT Publication Date:September 07, 2001PCT Publication Number: WO01/64656

Non-Orange Book US Patents Family Members for Patent 6,838,464

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,067,522 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,838,464

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 2005041878 ➤ Subscribe
Japan 4801335 ➤ Subscribe
Japan 2003525279 ➤ Subscribe
Israel 150920 ➤ Subscribe
South Korea 100855258 ➤ Subscribe
South Korea 20070106806 ➤ Subscribe
Hong Kong 1053111 ➤ Subscribe
United Kingdom 0004887 ➤ Subscribe
Spain 2346288 ➤ Subscribe
European Patent Office 1278735 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
US Department of Justice
Argus Health
McKesson
Chubb
Accenture
Cipla
Express Scripts
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot